References
- 1National Collaborating Centre for Mental Health (UK). Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (update). National Institute for Health and Clinical Excellence (NICE) Clinical Guidelines. No. 82. Leicester: British Psychological Society; 2009: 1-399.National Collaborating Centre for Mental Health (UK)Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (update)National Institute for Health and Clinical Excellence (NICE) Clinical GuidelinesNo. 82LeicesterBritish Psychological Society20091399
- 2WHO. World Health Organization International Classification of Diseases, 10th ed. Geneva: WHO; 1990.WHOWorld Health Organization International Classification of Diseases10thGenevaWHO1990
- 3Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2:el41.SahaSChantDWelhamJMcGrathJA systematic review of the prevalence of schizophreniaPLoS Med20052el41
- 4Years of lives with disability from mental disorders. Thailand 2004. Thailand International Health Policy Program. Nonthaburi: Ministry of Public Health; 2004. pp. 21. [Online] 2005 [cited 2015 October 30] Available from: www.thaibod.net/documents/YLD%20Mental%20disorders.pdfYears of lives with disability from mental disorders, Thailand2004Thailand International Health Policy ProgramNonthaburiMinistry of Public Health200421[Online] 2005 [cited 2015 October 30] Available fromwww.thaibod.net/documents/YLD%20Mental%20disorders.pdf
- 5Phanthunane P, Vos T, Whiteford H, Bertram M, Udomratn P. Schizophrenia in Thailand: prevalence and burden of disease. Popul Health Metr. 2010; 8: 24.2071290910.1186/1478-7954-8-24PhanthunanePVosTWhitefordHBertramMUdomratnPSchizophrenia in Thailand: prevalence and burden of diseasePopul Health Metr2010824
- 6Tandon RT, Targum SD, Nasrallah HA, Ross R; Treatment Effectiveness in Schizophrenia Consortium. Strategies for maximizing clinical effectiveness in the treatment of schizophrenia. J Psychiatr Prac. 2006; 12: 348-63.TandonRTTargumSDNasrallahHARossRTreatment Effectiveness in Schizophrenia ConsortiumStrategies for maximizing clinical effectiveness in the treatment of schizophrenia. J Psychiatr Prac20061234863
- 7Janicak PG, Davis JM, Preskorn SH, Ayd FJ. Principles and practice of psychopharmacotherapy. Baltimore: Williams and Wilkins; 1993, pp. 592.JanicakPGDavisJMPreskornSHAydFJPrinciples and practice of psychopharmacotherapyBaltimoreWilliams and Wilkins1993592
- 8Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence: incidence: and risk factors. Psychopharmacology. 1985; 2:72-8.KaneJMWoernerMLiebermanJTardive dyskinesia: prevalence: incidence: and risk factorsPsychopharmacology19852728
- 9Suvisaari JM, Saarni SI, Perala J, Suvisaari JV, Harkanen T, Lonnqvist J, et al. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry. 2007; 68:1045-55.10.4088/JCP.v68n0711SuvisaariJMSaarniSIPeralaJSuvisaariJVHarkanenTLonnqvistJet alMetabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population surveyJ Clin Psychiatry200768104555
- 10Meaney AM, O’Keane V. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophrenia Res. 2007; 93: 13643.10.1016/j.schres.2007.01.013MeaneyAMO’KeaneVBone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variablesSchizophrenia Res20079313643
- 11Disyavanish C, Srisurapanont M, Karnjanathanalers N, Theeramoke V, KongsakonR, Kittiratanapaibool P, et al. Thai schizophrenia treatment guidelines. In: Sukanit P, Udomrath P, editors. Clinical practice guidelines in psychiatric disorders. Bangkok: Beyond Enterprise; 2001: p. 67-90.DisyavanishCSrisurapanontMKarnjanathanalersNTheeramokeVKongsakonRKittiratanapaiboolPet alThai schizophrenia treatment guidelinesSukanitPUdomrathPClinical practice guidelines in psychiatric disordersBangkokBeyond Enterprise20016790
- 12LamY-WF, Velligan DI, Ereshefsky L. Intra-individual variability in plasma concentrations as an indicator of adherence in schizophrenia [abstract]. Poster presented at the 42nd Annual Meeting of New Clinical Drug Evaluation Unit (NCDEU) June 10-13, 2002; Boca Raton, FL, USA.LamY-WFVelliganDIEreshefskyLIntra-individual variability in plasma concentrations as an indicator of adherence in schizophrenia [abstract]Poster presented at the 42nd Annual Meeting of New Clinical Drug Evaluation Unit (NCDEU)June10132002Boca RatonFL, USA
- 13Weiden P, Glazer W. Assessment and treatment selection for O“revolving doorO” inpatients with schizophrenia. PsychiatrQ. 1997; 68:377-92.WeidenPGlazerWAssessment and treatment selection for O“revolving doorO” inpatients with schizophreniaPsychiatrQ19976837792
- 14Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Eng J Med. 2005; 353:1209-23.10.1056/NEJMoa051688LiebermanJAStroupTSMcEvoyJPSwartzMSRosenheckRAPerkinsDOet alEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Eng J Med2005353120923
- 15Kane JM. Treatment adherence and long-term outcomes. CNS Spectrums. 2007; 12:21-6.10.1017/S109285290002630417934386KaneJMTreatment adherence and long-term outcomesCNS Spectrums200712216
- 16Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry. 2008; 8:32.1844793510.1186/1471-244X-8-32MorkenGWidenJHGraweRWNon-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophreniaBMC Psychiatry2008832
- 17Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23:3105-24.1544933810.1002/sim.1875LuGAdesAECombination of direct and indirect evidence in mixed treatment comparisonsStat Med200423310524
- 18Jansen JP, Crawford B, Bergman G, Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 2008; 11:956-64.1848949910.1111/j.1524-4733.2008.00347.xJansenJPCrawfordBBergmanGStamWBayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisonsValue Health20081195664
- 19Leucht S, Cipriani A, Spineli L, Mavridis D, rey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013 ; 3 82:951-62.2381001910.1016/S0140-6736(13)60733-3LeuchtSCiprianiASpineliLMavridisDreyDRichterFet alComparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisLancet201338295162
- 20Ades AE, Mavranezouli I, Dias S, Welton NJ, Whittington C, Kendall T. Network meta-analysis with competing risk outcomes. Value Health. 2010; 13 : 976-83.10.1111/j.1524-4733.2010.00784.x20825617AdesAEMavranezouliIDiasSWeltonNJWhittingtonCKendallTNetwork meta-analysis with competing risk outcomesValue Health20101397683
- 21Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17:1-12.10.1016/0197-2456(95)00134-48721797JadadARMooreRACarrollDJenkinsonCReynoldsDJGavaghanDJet alAssessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials199617112
- 22Dias S, Welton NJ, Sutton AJ, Ades A. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. [On line]. 2011 [last updated April 2012; cited 2015 October 31]. 2011; 20111893, Available from www.nicedsu.org.ukresearch-information.bristol.ac.uk/files/7215331TSD2_General_meta_analysis.final.08.05.12.pdfDiasSWeltonNJSuttonAJAdesANICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials[On line]. 2011 [last updated April 2012; cited 2015 October 31]201120111893www.nicedsu.org.ukresearch-information.bristol.ac.uk/files/7215331TSD2_General_meta_analysis.final.08.05.12.pdf
- 23Welton NJ, Sutton AJ, Cooper N, Abrams KR, Ades AE. Evidence synthesis for decision making in healthcare. Statistics in Practice (series), volume 126. Hoboken: Wiley; 2012.WeltonNJSuttonAJCooperNAbramsKRAdesAEEvidence synthesis for decision making in healthcareStatistics in Practice (series)126HobokenWiley2012
- 24Hirsch SR, Gaind R, Rohde PD, Stevens BC, Wing JK. Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial, report to the Medical Research Council Committee on Clinical Trials in Psychiatry. BMJ. 1973; 1:633-7.10.1136/bmj.1.5854.633HirschSRGaindRRohdePDStevensBCWingJKOutpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial, report to the Medical Research Council Committee on Clinical Trials in PsychiatryBMJ197316337
- 25Odejide OA, Aderounmu AF. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. J Clin Psychiatry. 1982; 43: 195-6.7076630OdejideOAAderounmuAFDouble-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patientsJ Clin Psychiatry1982431956
- 26Sampath G, Shah A, Krska J, Soni SD. Neuroleptic discontinuation in the very stable schizophrenic patient: Relapse rates and serum neuroleptic levels. Hum Psychopharmacol. 1992;7:255-64.10.1002/hup.470070405SampathGShahAKrskaJSoniSDNeuroleptic discontinuation in the very stable schizophrenic patient: Relapse rates and serum neuroleptic levelsHum Psychopharmacol1992725564
- 27Eberhard G, Hellbom E. Haloperidol decanoate and flupenthixol decanoate in schizophrenia. A long-term double-blind cross-over comparison. Acta Psychiatr Scand 1986; 74:255-62.EberhardGHellbomEHaloperidol decanoate and flupenthixol decanoate in schizophreniaA long-term double-blind cross-over comparison. Acta Psychiatr Scand19867425562
- 28Chouinard G, Annable L, Campbell W. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. J Clin Psychopharmacol. 1989;9:247-53.2570086ChouinardGAnnableLCampbellWA randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophreniaJ Clin Psychopharmacol1989924753
- 29Chouinard G, Annable L, Campbell W, Boisvert D, Bradwejn J. A double-blind controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia. In: Pichot P, editor. Psychiatry: the state of the art. Proceedings of the 7th World Congress of Psychiatry, held July 11-16,1983, in Vienna, Austria, 3rdEdition New York: PlenumPress; 1985, p. 759-61.ChouinardGAnnableLCampbellWBoisvertDBradwejnJA double-blind controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophreniaPichotPPsychiatry: the state of the art. Proceedings of the 7th World Congress of Psychiatry, held July 11-16,1983, in Vienna, Austria3rdNew YorkPlenumPress198575961
- 30Cookson JC, Kennedy NM, Gribbon D. Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate. Int Clin Psychopharmacol. 1986; l(Suppl. 1):41-51.3549879CooksonJCKennedyNMGribbonDWeight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoateInt Clin Psychopharmacol19861Suppl. 14151
- 31Jolley AG, Hirsch SR, Morrison E, McRink A, Wilson L. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ. 1990;301:837-42.228242110.1136/bmj.301.6756.837JolleyAGHirschSRMorrisonEMcRinkAWilsonLTrial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two yearsBMJ199030183742
- 32Jolley AG, Hirsch SR, McRink A, Manchanda R. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. BMJ. 1989;298:985-90.10.1136/bmj.298.6679.9852567190JolleyAGHirschSRMcRinkAManchandaRTrial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one yearBMJ198929898590
- 33Kissling W, Moller HJ, Walter K, Wittmann B, Krueger R, Trenk D. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months’ treatment for relapse prevention. Pharmacopsychiatry. 1985; 18:240-5.10.1055/s-2007-10173734011672KisslingWMollerHJWalterKWittmannBKruegerRTrenkDDouble-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months’ treatment for relapse preventionPharmacopsychiatry1985182405
- 34McKane JP, Robinson AD, Wiles DH, McCreadie RG, Stirling GS. Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients. Br J Psychiatry. 1987; 151: 333-6.332246710.1192/bjp.151.3.333McKaneJPRobinsonADWilesDHMcCreadieRGStirlingGSHaloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patientsBr J Psychiatry19871513336
- 35Sharma SK, Jaigirdar SH. A comparison of fluphenazine decanoate and haloperidol decanoate in chronic schizophrenia. Br J ClinRes. 1991; 2:177-86.SharmaSKJaigirdarSHA comparison of fluphenazine decanoate and haloperidol decanoate in chronic schizophreniaBr J ClinRes1991217786
- 36Fleischhacker WW, Gopal S, Lane R, Gassmann-Mayer C, Lim P, Hough D, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol. 2012; 15:107-18.2177750710.1017/S1461145711001076FleischhackerWWGopalSLaneRGassmann-MayerCLimPHoughDet alA randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophreniaInt J Neuropsychopharmacol20121510718
- 37Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010; 116: 107-17.1995933910.1016/j.schres.2009.10.026HoughDGopalSVijapurkarULimPMorozovaMEerdekensMPaliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled studySchizophr Res201011610717
- 38Pinto R, Bannerjee A, Ghosh N. A double-blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia. Acta Psychiat Scand. 1979;60:313-22.10.1111/j.1600-0447.1979.tb00281.xPintoRBannerjeeAGhoshNA double-blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophreniaActa Psychiat Scand19796031322
- 39Wistedt B, Ranta J. Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology. Acta Psychiat Scand. 1983; 67: 378-88.10.1111/j.1600-0447.1983.tb09718.xWistedtBRantaJComparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatologyActa Psychiat Scand19836737888
- 40Wistedt B, Koskinen T, Thelander S, Nerdrum T, Pedersen V, M lbjerg C. Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study. Acta Psychiat Scand. 1991;84:14-21.10.1111/j.1600-0447.1991.tb01414.xWistedtBKoskinenTThelanderSNerdrumTPedersenV, MlbjergCZuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre studyActa Psychiat Scand1991841421
- 41Eklund K, Forsman A. Minimal effective dose and relapse—double-blind trial: haloperidol decanoate vs. placebo. Clin Neuropharmacol. 1991; 14 (Suppl. 2): S7-12; discussion S12-15.EklundKForsmanAMinimal effective dose and relapse—double-blind trial: haloperidol decanoate vs. placeboClin Neuropharmacol199114Suppl. 2S7-12S12-15
- 42Dencker SJ, Lepp M, Malm U. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. I. A one year double-blind study of clopenthixol decanoate and flupenthixol palmitate. Acta Psychiat Scand Suppl. 1980; 279:10-28.DenckerSJLeppMMalmUClopenthixol and flupenthixol depot preparations in outpatient schizophrenicsI. A one year double-blind study of clopenthixol decanoate and flupenthixol palmitate. Acta Psychiat Scand Suppl19802791028
- 43Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012; 379:2063-71.2256060710.1016/S0140-6736(12)60239-6LeuchtSTardyMKomossaKHeresSKisslingWSalantiGet alAntipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysisLancet2012379206371
- 44Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382:951-62.2381001910.1016/S0140-6736(13)60733-3LeuchtSCiprianiASpineliLMavridisDOreyDRichterFet alComparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisLancet201338295162
- 45Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophrenia Bull. 2014; 40:192-213.10.1093/schbul/sbs150KishimotoTRobenzadehALeuchtCLeuchtSWatanabeKMimuraMet alLong-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trialsSchizophrenia Bull201440192213
- 46Woods BS, Hawkins N, Scott DA. Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. BMC. 2010; 10:54.WoodsBSHawkinsNScottDANetwork meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorialBMC20101054